Rectodelt 100 rectal suppositories, 100 mg each, No. 2

In stock: 1
$70.00

Composition

Active ingredient: prednisone;

1 suppository contains 100 mg of prednisone;

excipient: hard fat.

Dosage Form

Rectal suppositories.

Main physical and chemical properties: torpedo-shaped suppositories with a smooth surface.

Pharmacotherapeutic group

Corticosteroids for systemic use. Glucocorticoids. ATC code H02A B07.

Pharmacological properties

Pharmacodynamics.

Prednisone is a fluorine-free glucocorticoid intended for systemic use.

Prednisone has a dose-dependent effect on the metabolism of nearly all tissues. At physiological levels, its action is necessary to maintain the body’s homeostasis at rest and during physical exertion, as well as to regulate the activity of the immune system.

At doses exceeding the level required for replacement therapy, prednisone exhibits a rapid anti-inflammatory effect (antiexudative and antiproliferative effects) and a delayed immunosuppressive effect. It inhibits chemotaxis and the activity of immune system cells, as well as the release and effects of mediators of inflammation and immune responses, such as lysosomal enzymes, prostaglandins, and leukotrienes.

In cases of bronchial obstruction, prednisone enhances the action of beta-agonists with a bronchodilator effect (permissive action).

Long-term treatment with high doses leads to atrophy of the immune system and the adrenal cortex.

The mineralocorticoid effect (significant for hydrocortisone, noticeable for prednisone) may require monitoring of serum electrolytes.

The effect of prednisone on airway obstruction is balanced by the slowing of inflammatory processes, the suppression or prevention of mucosal edema, inhibition of bronchial stenosis, inhibition or reduction of mucus production, and a decrease in mucus viscosity. This effect is based on the following mechanism: a reduction in vascular permeability and stabilization of the cell membrane, normalization of the sensitivity of bronchial muscles to β2-sympathomimetics if it has decreased due to their prolonged use, and suppression of Type I reactions beginning in the second week of treatment.

Pharmacokinetics.

Absorption: Corticosteroid levels in blood plasma can be detected shortly after administration of the “RectoDelt 100” suppository.

Metabolism: After administration, prednisone is rapidly metabolized to prednisolone. In general, prednisone and prednisolone are interconverted in the body, with prednisolone accounting for the larger proportion. Absolute bioavailability is approximately 29%.

Distribution: Prednisolone binds to transcortin and plasma proteins. The volume of distribution is approximately 1.5 mL/min/kg.

Excretion: Approximately 2–5% of the absorbed dose is excreted in the urine as prednisone, approximately 11–24% as prednisolone, and the remainder as other metabolites.

Indications

“Rektodelt 100” suppositories are indicated for children for the intensive treatment of pseudocroup (acute stenotic laryngotracheitis), croup, and spastic bronchitis.

Contraindications

Hypersensitivity to prednisone or to any other ingredient in the medication. When prednisone is used for a short period to treat acute, potentially life-threatening, and urgent conditions, there are no other contraindications.

Parasitic and infectious diseases of viral, fungal, or bacterial origin, whether current or recently past: herpes simplex, herpes zoster (viremic phase), chickenpox, measles; amebiasis, strongyloidiasis (confirmed or suspected); systemic mycosis; active or latent tuberculosis.

Post-vaccination period (10 weeks in total: 8 weeks before and 2 weeks after vaccination), lymphadenitis following BCG vaccination.

Immunodeficiency states caused by HIV infection.

Cardiovascular diseases: recent myocardial infarction, decompensated chronic heart failure, hypertension, predisposition to thromboembolic disease.

Endocrine system disorders: diabetes mellitus and impaired glucose tolerance, thyrotoxicosis, hypothyroidism, Cushing’s syndrome.

Severe chronic renal and/or hepatic insufficiency; nephro-urolithiasis.

Hypoalbuminemia. Systemic osteoporosis. Myasthenia gravis. Acute psychosis. Obesity (stages III–IV). Poliomyelitis (excluding the bulbar encephalitis form). Open-angle and closed-angle glaucoma.

Drug Interactions and Other Interactions

Enzyme inducers, such as barbiturates, phenytoin, primidone, carbamazepine, and rifampicin, may reduce the effects of “Rektodelt 100.”

Estrogens may enhance the clinical and toxic effects of “Rektodelta 100.”

Concomitant use of “Rektodelt 100” with atropine or other anticholinergic drugs, along with antihistamines or nitrates, may cause an increase in intraocular pressure and a decrease in the effectiveness of antihistamines.

Concomitant use with salicylates or nonsteroidal anti-inflammatory drugs (NSAIDs) increases the risk of gastrointestinal bleeding.

The effects of antidiabetic agents, insulin, and coumarin derivatives may be reduced when taken concomitantly with “Rektodelt 100.”

Concomitant use with cardiac glycosides may enhance glycoside activity associated with steroid-induced potassium loss.

Concomitant use with antacids reduces the absorption of prednisone and prednisolone.

When used concomitantly with diuretics, laxatives, or amphotericin B, an increase in potassium loss is possible. It increases the risk of osteoporosis when used concomitantly with amphotericin B and carbonic anhydrase inhibitors.

Corticosteroids may lead to a decrease in the blood concentrations of isoniazid, mexiletine, and praziquantel.

When used concomitantly with angiotensin-converting enzyme (ACE) inhibitors, the risk of changes in blood counts increases. Reduced efficacy of antihypertensive drugs.

Chloroquine, hydroxychloroquine, and mefloquine increase the risk of myopathies and cardiomyopathies.

The effect of somatotropin may be reduced.

The effect of protirelin on increasing thyrotropin (TSH) levels may be reduced.

Blood levels of cyclosporine increase, and the risk of cerebral seizures increases.

Tricyclic antidepressants may exacerbate symptoms of depression caused by prednisolone and increase intraocular pressure.

Immunosuppressants increase the risk of infections and lymphoma or other lymphoproliferative disorders associated with the Epstein-Barr virus.

Neuroleptics, carbamide, and azathioprine increase the risk of developing cataracts.

Estrogens, anabolic steroids, and oral contraceptives may cause hirsutism and acne.

Live antiviral vaccines and other types of immunizations increase the risk of viral activation and the development of infections.

Concomitant use with muscle relaxants in the presence of hypokalemia increases the severity and duration of muscle blockade caused by muscle relaxants;

with anticholinesterase agents—may cause muscle weakness in patients with myasthenia (especially in patients with myasthenia gravis);

with mitotane and other adrenal cortex inhibitors—may require an increase in the drug dose;

with antiemetics – increased antiemetic effect;

with fluoroquinolones – tendon damage.

During long-term therapy, prednisolone increases folic acid levels.

The drug reduces the effect of vitamin D on Ca2+ absorption in the intestinal lumen.

Concomitant administration of glucocorticoids and CYP3A inhibitors, including drugs containing cobicistat, is expected to increase the risk of systemic adverse reactions.

Cases of Cushing’s syndrome and adrenal suppression have been reported.

Such interactions should be avoided unless the benefit outweighs the increased risk of adverse effects associated with the use of systemic glucocorticoids; in such cases, patients should be monitored for adverse effectsassociated with the use of systemic glucocorticoids.

Special Considerations for Use

“Rectodelt 100” should be used primarily for acute conditions. Use of “Rectodelt 100” is permitted only after a thorough risk-benefit analysis. Long-term use (more than 2 days) is permitted only under strict medical supervision.

A positive doping test is possible while taking “Rectodelt 100.”

Pheochromocytoma crisis: A pheochromocytoma crisis, which can be fatal, may occur following the use of systemic corticosteroids. Corticosteroids should be prescribed only to patients with suspected or confirmed pheochromocytoma after an appropriate risk-benefit assessment.

Visual disturbances may occur with systemic and topical use of corticosteroids. If a patient experiences symptoms such as blurred vision or other visual disturbances, the patient should be referred to an ophthalmologist to evaluate possible causes, which may include cataracts, glaucoma, or rare conditions such as central serous chorioretinopathy (CSCR), which have been reported following the use of systemic and topical corticosteroids.

Scleroderma renal crisis: Caution is advised when treating patients with systemic sclerosis due to an increased incidence of scleroderma renal crisis with hypertension (which may be fatal) and a decrease in urine output at a daily dose of prednisolone of 15 mg or more. Blood pressure and renal function (serum creatinine) should therefore be monitored regularly. If a renal crisis is suspected, blood pressure should be closely monitored.

Use during pregnancy or breastfeeding.

There are insufficient data on the use of the drug “Rektodelt 100” during pregnancy. In animal studies, systematic use of prednisone caused embryotoxic and teratogenic effects. Typical embryotoxic and teratogenic effects observed in animal studies with other glucocorticoids, aside from prednisone, included “wolf mouth,” skeletal abnormalities, intrauterine growth retardation, embryonic mortality.

An increased risk of cleft lip and palate in human embryos has also been noted as a result of systemic glucocorticoid use during the first trimester. Animal studies have also shown that the use of subteratogenic doses during pregnancy increases the risk of intrauterine growth restriction, cardiovascular disease and metabolic disorders in adults, as well as long-term changes in glucocorticoid receptor density, nerve impulse transmission, and reactions.

If glucocorticoids are used during the third trimester, there is a risk of adrenal cortex atrophy. In such cases, the dose of replacement therapy for the newborn must be reduced.

Therefore, Rectodelt 100 may be used during pregnancy only after a careful risk-benefit analysis.

Prednisone and prednisolone pass into breast milk. There are no data on adverse effects on the newborn. If higher doses are necessary, breastfeeding must be discontinued.

Effect on reaction time when driving or operating machinery.

“Rectodelt 100” does not affect reaction time when driving or operating machinery.

Dosage and Administration

For children aged 6 months and older, administer 1 suppository per day, equivalent to 100 mg of prednisone. The duration of treatment depends on the course of the disease. In acute conditions, short-term therapy is generally sufficient. If necessary, repeat the treatment once. Further use is not recommended. Treatment with “Rektodelt 100” suppositories should not exceed 2 days (equivalent to 200 mg of prednisone).

Suppositories should be inserted deeply into the rectum.

Rectal administration is particularly recommended for young children when intravenous, intramuscular, or oral administration of glucocorticoids causes difficulties and additional stress in children.

Do not exceed the recommended dose or duration of treatment. Failure to follow these recommendations may result in serious adverse reactions (see the “Adverse Reactions” section).

Children.

This medication is indicated for children 6 months of age and older.

Overdose

Acute prednisone intoxication has not been reported to date. The risk of overdose increases with prolonged use of the drug, especially at high doses.

In the event of an overdose, consider the possibility of increased side effects, primarily involving the endocrine system, as well as disturbances in metabolism and electrolyte balance.

Symptoms: increased blood pressure, peripheral edema, and increased side effects.

Treatment of overdose: immediate gastric lavage or induction of vomiting. There is no specific antidote.

Side Effects

In cases of emergency treatment, the only possible side effect may be:

Immune system: hypersensitivity to “Rectodelt 100.”

Long-term use of glucocorticoids may cause the following side effects:

Endocrine system: Cushing’s syndrome of varying severity, with manifestations such as a moon-shaped face, obesity, development of diabetic metabolic syndrome, hyperglycemia up to the development of steroid-induced diabetes, depletion (up to atrophy) of adrenal cortex function, growth retardation in children, impaired secretion of sex hormones, hirsutism, and changes in blood counts;

metabolic effects: hypokalemia, sodium and fluid retention, negative nitrogen balance;

Cardiovascular system: increased blood pressure, bradycardia (with high doses);

Coagulation system: increased blood clotting;

Musculoskeletal system: aseptic bone necrosis, osteoporosis, muscle atrophy;

Gastrointestinal system: gastric or intestinal ulcers (due to ulcerogenic effects on the gastrointestinal tract and increased gastric acidity), pancreatitis;

Skin: skin changes (skin atrophy, telangiectasia, striae, acne; hematomas, bruises, skin discoloration);

Cardiovascular system: vascular fragility;

Ocular: steroid-induced cataracts, triggering of latent glaucoma;

Central nervous system: psychiatric disorders.

Effects due to immunosuppressive action: decreased resistance to infections, delayed wound healing.

Prednisolone

The frequency and severity of side effects depend on the duration of treatment, the dose used, and the ability to adhere to a circadian rhythm of administration:

Cardiovascular system: arrhythmia, bradycardia, hypertension, development or worsening of chronic heart failure, ECG changes characteristic of hypokalemia. In patients with acute and subacute myocardial infarction—spread of the necrotic focus, delayed scar formation, which may lead to rupture of the heart muscle;

In the hematological and lymphatic systems: leukocyturia, hypercoagulation leading to thrombosis and thromboembolism;

Neurological system: headache, dizziness, cerebellar pseudotumor, increased intracranial pressure, seizures;

Ocular system: posterior subcapsular cataract, increased intraocular pressure with possible damage to the optic nerve, susceptibility to secondary bacterial, fungal, or viral eye infections, trophic changes in the cornea, exophthalmos;

Gastrointestinal system: nausea, vomiting, epigastric pain, diarrhea, pancreatitis, “steroid-induced” gastric and duodenal ulcers, erosive esophagitis, gastrointestinal bleeding and perforation, increased or decreased appetite, flatulence, hiccups. In isolated cases—elevated levels of liver transaminases and alkaline phosphatase;

skin and subcutaneous tissue disorders: delayed wound healing, petechiae, bruises, hematomas, ecchymoses, striae, skin thinning, hyper- or hypopigmentation, acne, predisposition to pyoderma;

Musculoskeletal and connective tissue disorders: slowed growth and ossification in children (premature closure of epiphyseal growth plates), osteoporosis, very rarely—pathological bone fractures, aseptic necrosis of the humeral or femoral head; muscle tendon ruptures, “steroid” myopathy, and decreased muscle mass (atrophy);

Endocrine system: decreased glucose tolerance, “steroid” diabetes mellitus or manifestation of latent diabetes mellitus, suppression of the hypothalamic-pituitary-adrenal axis, menstrual cycle disorders, slowed growth in children and adolescents, delayed sexual development in children, Cushing’s syndrome (moon face, pituitary-type obesity, hirsutism, elevated blood pressure, dysmenorrhea, amenorrhea, myasthenia gravis, striae);

metabolic effects: hypocalcemia, negative nitrogen balance (increased protein breakdown), weight gain. Side effects caused by the glucocorticosteroid activity of prednisolone: fluid and sodium retention (peripheral edema), hypernatremia, hypokalemic syndrome—arrhythmia, myalgia or muscle spasms, unusual weakness and fatigue;

infections and infestations: decreased resistance to infections;

Immune system: rash, itching, erythema, urticaria, angioedema, anaphylactic shock;

psychiatric disorders: delirium, disorientation, euphoria, hallucinations, manic-depressive psychosis, depression, paranoia, nervousness, restlessness, insomnia;

Other: withdrawal syndrome, edema, aphthous ulcers, increased risk of urolithiasis;

Ocular: blurred vision (see the “Special Considerations for Use” section);

Renal and urinary tract disorders: scleroderma-associated renal crisis (see the “Special Considerations for Use” section). The incidence of scleroderma-associated renal crisis varies among different subpopulations. The highest risk is observed in patients with diffuse systemic sclerosis. The lowest risk was reported in patients with limited systemic sclerosis (2%) and juvenile systemic sclerosis (1%).

Postmarketing reporting of adverse reactions is important. It allows for monitoring the benefit-risk profile of this medication. Healthcare and pharmaceutical professionals, as well as patients or their legal representatives, should report all cases of suspected adverse reactions and lack of efficacy of the drug through the automated pharmacovigilance information system at the following link: https://aisf.dec.gov.ua/.

Shelf life

3 years.

Storage conditions

Store at a temperature not exceeding 25 °C.

Keep out of reach of children.

Packaging

2 or 6 suppositories per blister pack; 1 blister pack per cardboard box.

 

Manufacturer

Trommsdorf GmbH & Co. KG, Germany.

Address

Trommsdorffstrasse 2–6, 52477 Alsdorf, Germany.